By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Frequency Therapeutics 

300 Technology Square, 8th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: Fax:


SEARCH JOBS

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital.

YEAR FOUNDED:

2015

LEADERSHIP:

Co-founder and CEO: David Luccino

Co-founder and CSO: Chris Loose, Ph.D.

Co-founder and Vice President, Biology and Regenerative Medicine: Will Mclean, Ph.D.

COO: Michael Jirousek, Ph.D.

CMO: Peter C. Weber, M.D., M.B.A.

Senior Vice President, Drug Development and Technical Operations: Raj Manchanda, Ph.D.

TECHNOLOGY:

Please click here for Frequency Therapeutics' technology.


Key Statistics


Email: frequencytx@macbiocom.com
Ownership: Private

Web Site: Frequency Therapeutics
Employees:
Symbol: 
 



Industry
Biotechnology






Company News
//-->